With a formidable new competitor set to enter the orexin development race, Takeda is out with new data it hopes reinforces market-leading potential.
With a formidable new competitor set to enter the orexin development race, Takeda is out with new data it hopes reinforces market-leading potential.
The additional …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
Phase 1 MRX1 Study Delivers Strong Headline Data
FDA hearing on Amgen's Tavneos will include findings from an independent review
Fierce Pharma Asia—Astellas CEO’s 5-year plan; Takeda’s psoriasis win; RA’s China bridge program
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with…
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
Phase 1 MRX1 Study Delivers Strong Headline Data
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Design Therapeutics shares Phase 1/2 data in Friedreich ataxia; Vincentage Pharma, a new China obesity player, emerges with Phase…
